19 May 2013
Keywords: cordis, drug-eluting, stent, get, incremental, reimbursement, subsidiary
Article | 05 August 2002
In what Cordis, a subsidiary of Johnson & Johnson, describes as a"precedent-setting decision" by the US Department of Health and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 August 2002
17 May 2013
© 2013 thepharmaletter.com